Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Safety of fruquintinib monotherapy and combination therapy in Chinese patients with colorectal cancer in real-world clinical practice: A subgroup analysis from phase IV study.

Zhiqiang Wang, Haijun Zhong, Yifu He et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15515

e15515 Background: Although Fruquintinib (Fru) monotherapy is one of the standard treatments for third line mCRC patients(pts), combination of Fru and oth...

Comparative trends in brain and CNS cancer across high-income countries: A benchmarking study (1990-2021).

Hardik Jain, Madhu Bhargavi Chandra, Siddhant Jain et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22504

e22504 Background: Brain and central nervous system (CNS) cancer poses a significant public health challenge, particularly in high-income countries (HIC)...

HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial.

Min Yan, Huimin Lv, Huiping Li et al. Jun 01, 2025 pp. 1017-1017 10.1200/jco.2025.43.16_suppl.1017

1017 Background: HER2-directed antibody-drug conjugates (ADCs) have been demonstrated to be of intracranial activity in patients with HER2+ breast cancer...

Trends and disparities in polycythemia vera–related mortality in the United States from 1999 to 2020.

Iqra Shahid, Faiza Fatima, Ayeza Nawaz et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22557

e22557 Background: Polycythemia Vera (PV) is a rare JAK2-mutated myeloproliferative neoplasm with a 5-year survival rate of approximately 79.5%. Patients...

Impact of stromal-targeting antitumor CAR T cells in solid tumors.

Abdul Khan, Thoihen Meitei Heikrujam, Renier J. Brentjens Jun 01, 2025 pp. 2541-2541 10.1200/jco.2025.43.16_suppl.2541

2541 Background: While chimeric antigen receptor (CAR) T cells have shown tremendous success in hematological malignancies, but such efficacy has not been...

Single-cell transcriptomic architecture for deciphering the complexity of tumor microenvironment in ampulla of Vater carcinoma.

Hyemin Kim, Young Hoon Choi, Hyoung-oh Jeong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16474

e16474 Background: Ampulla of Vater carcinoma (AVC) is a rare gastrointestinal tumor that is associated with a high mortality rate and it’s often diagnose...

A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not.

Wangxia Lv, Bixia Liu, Tingting Feng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15530

e15530 Background: Fruquintinib (Fru) is a VEGFR1/2/3 inhibitor and has been approved in USA for third-line treatment of mCRC based on FRESCO-2 data. Rego...

Analysis of MFGE8 expression and regional localization in glioblastoma tumor samples at diagnosis and relapse.

Rakan Okde, Patrick Laplante, Jean-Paul Bahary et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14016

e14016 Background: Milk fat globule-EGF factor 8 protein (MFGE8) is an immunomodulatory protein with an increasingly recognized role in cancer. It plays a...

Targeted therapies for metastatic pheochromocytoma and paraganglioma: A systematic review and meta-analysis.

Amelito Manuel Andaya, Fawwad Ansari, Nimeshi Fernando et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16346

e16346 Background: Pheochromocytomas and paragangliomas are neuroendocrine tumors that have similar histopathology and clinical course. They also have com...

Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).

Daniel Bsteh, Jonathan Buckley, Scott Mitchell et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17111

e17111 Background: Parallel analysis of cfDNA and ctcDNA can yield expanded and complementary molecular insights. We developed HERCULES, a prostate cancer...

Cancer care quality perception among cancer survivors: Impact of provider time spent and shared decision making.

Onyema Chido-Amajuoyi, Henry Onyeaka, Crystal Okpagu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23158

e23158 Background: This study evaluates cancer survivors’ perception of their cancer care quality, as well as the factors that predict cancer care quality...

Regorafenib and nivolumab in refractory microsatellite stable, metastatic colorectal cancer and impact of site of dominant disease.

Usman Shah, Sam Skariah Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15594

e15594 Background: Several studies have explored the role of Regorafenib and Nivolumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)....

Body mass index and somatic variants in biliary tract cancers.

Layal Al Mahmasani, Joanne F. Chou, Marinela Capanu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14636

e14636 Background: Obesity is postulated to exacerbate the oncogenic effects of select oncogenes. The metabolic and inflammatory changes associated with o...

Transcatheter arterial chemoembolization plus donafenib and sintilimab for unresectable hepatocellular carcinoma: A prospective, single-arm, phase II study.

Xiaoyun Hu, Guosheng Yuan, Kunyuan Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16186

e16186 Background: Although combination therapy with anti-angiogenic agents and immune checkpoint inhibitors has become the standard treatment for unresec...

The use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin based chemoradiation: Landmark 3-year survival analysis of a randomized phase III trial (DHANUSH).

Sneha Dhar, Vanita Noronha, Minit Jalan Shah et al. Jun 01, 2025 pp. 6086-6086 10.1200/jco.2025.43.16_suppl.6086

6086 Background: Patients with cisplatin-ineligible locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have limited guideline-recommended t...

Using consideRATE to evaluate patient experience in a cancer center: Psychometric and healthcare assessments.

Joseph Nano, Gabrielle Stevens, Glyn Elwyn et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23203

e23203 Background: conside RATE is a patient- and care-partner-reported measure of care experience during serious illness. We used consideRATE...

Plasma cell leukemia: Updates on demographics and prognostication.

Shammas Bajwa, Hassan Ali, Umair Farooq Bajwa et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19555

e19555 Background: Plasma cell leukemia (PCL) is an uncommon and highly aggressive form of multiple myeloma characterized by the presence of ≥5% circulati...

Demographic variation in molecular profiles of tumors from metastatic colon cancer patients.

Jankikeerthika Muthukaruppan Dharmarpandi, Nam Huynh, Sharity Ondrejik et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15528

e15528 Background: Hispanic patients constitute one of the minority ethnic groups in metastatic colon cancer research and are underrepresented in clinical...

Stromal sarcoma, NOS: A National Cancer Database analysis of patient demographics and survival.

Anaum Showkat, Nikhita Tandon, Akaash Surendra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17637

e17637 Background: Stromal sarcoma (SS) is a rare malignancy of connective tissue, with endometrial stromal sarcoma representing approximately 10% of uter...

Transcatheter aortic valve replacement in cancer patients with chest radiation therapy: Risks and outcomes.

Saad Farooq, Muneeb Khawar, Umad Ali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24020

e24020 Background: Transcatheter aortic valve replacement (TAVR) is a widely adopted treatment for severe aortic stenosis, but outcomes in cancer survivor...

Trends and disparities in tracheal, bronchus, and lung cancer attributable to occupational carcinogens in the United States: A cross-state comparative analysis over three decades.

Aditya Ahuja, Dhruvkumar Gadhiya, Abdul Aleem et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22517

e22517 Background: Tracheal, Bronchus, and Lung Cancer (TBL) are the primary causes of death and disability in the United States, accounting for nearly 25...

A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.

Matteo S. Carlino, Reinhard Dummer, Tanja Gromke et al. Jun 01, 2025 pp. 9509-9509 10.1200/jco.2025.43.16_suppl.9509

9509 Background: GNAQ/11 mutations occur in up to 95% of uveal melanomas (UM) and a subset of non-uveal melanomas. Cell surface PMEL17 (gp100) is highly a...

Prospective feasibility study on delayed selective sentinel node biopsy for patients undergoing mastectomy for ductal carcinoma in situ.

Eunhye Kang, Hyelim Kang, Min Jung Lee et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12567

e12567 Background: In patients with ductal carcinoma in situ (DCIS) undergoing total mastectomy, sentinel lymph node biopsy (SLNB) is typically performed...

Kras-mutant oncolytic virus vaccine therapy for metastatic colorectal cancer: A preclinical study.

Jie Gao, Xianling Guo, Hua Zhang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15547

e15547 Background: Kirsten rat sarcoma (KRAS) mutations lead to aberrant activation of the RAS/RAF/MEK/ERK signaling pathway, promoting cell proliferation...

Remote physiologic and behavioral monitoring to predict early treatment response in metastatic cancer: High-Definition Oncology study (HDOs) preliminary results.

Leire Paz-Arbaizar, María Sauras, Sonia Pernas et al. Jun 01, 2025 pp. 1651-1651 10.1200/jco.2025.43.16_suppl.1651

1651 Background: Emerging evidence suggests that behavioral, physiologic or emotional factors may act as real-time indicators of treatment response, with...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page